Menu

Recent Interviews

Andrew Davidson, CEO, Royal Helium Limited

Andrew Davidson
CEO | Royal Helium Limited
224, 4th Avenue South, S7K 5M5 Saskatoon (CAN)

davidson@royalheliumltd.com

+1 (306) 281-9104

Royal Helium CEO Andrew Davidson on NASA, SpaceX and the path to dynamic growth


Craig Taylor, CEO, Defense Metals

Craig Taylor
CEO | Defense Metals
605-815 Hornby St., V6Z 1T9 Vancouver (CAN)

craig@defensemetals.com

+1 (778) 994 8072

Milestones, ESG as an USP and the new openness of policy toward rare earths outside China - Defense Metals provides backgrounds


Alex Kent, Managing Director, Aspermont Limited

Alex Kent
Managing Director | Aspermont Limited
613 - 619 Wellington Street, WA, 6000 Perth (AUS)

Corporate@aspermont.com

+61 8 6263 9100

Aspermont shows the success of digitalization - Alex Kent has an agenda


11. November 2020 | 13:22 CET

NEL ASA, dynaCERT, Bayer: Reallocation offers excellent opportunities

  • Investments
Photo credits: pixabay.com

After yesterday's triumphant announcement regarding a possible vaccine against the Corona Virus, a rift in the stock market seems to be in full swing. Highly praised tech shares and the profiteers of the Corona Crisis are falling through the bank. In contrast, there is a rebirth of the old economy and cyclical stocks. Oil stocks are also picking up again. The hope for an economic revival is becoming more tangible and creates excellent opportunities for the Fallen Angels.

time to read: 3 minutes by Stefan Feulner


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


Climate change mainstream again

The Corona Pandemic has been the number one topic of conversation in recent months; however, climate change will likely find its way back into mainstream media once life normalizes again. "Fridays For Future" and Greta, will once again call for the world to be saved, and politicians who are currently acting as corona saviors, such as Bavarian Prime Minister Markus Söder, will once again put the ban of the internal combustion engine on the agenda.

Green technology and hydrogen

This is precisely where dynaCERT Inc., which was founded in 2001, comes in. The basic idea of the Canadians is to reduce the pollutant emissions of diesel-powered vehicles. For this purpose, retrofitting units for diesel engines have been developed which use hydrogen as a catalyst. This reduces both fuel consumption and CO2 emissions in peak times, by up to 20%.

Trucks (still) in the foreground

The target group of dynaCERT is, however, not yet the millions of passenger cars, but primarily fleet operators. The goal is to retrofit the millions of trucks still running on diesel. With the specially developed software "HydraLitica" (TM) it is possible to monitor the fuel savings. Building on this platform, the Company recently announced additional services such as fleet management, route planning, driver safety and load management. The Company's technology is currently being tested in more than 400 vehicles.

Analysts extremely bullish

The analyst firm GBC Research seems to be highly impressed. The experts set the dynaCERT share at a clear buy. The target price was set at no less than CAD 2.20 by the end of 2021. As of yesterday, the share price was at CAD 0.50, offering considerable upside potential. The Canadians have definitely taken the pulse of the times.

Insiders started buying

At the moment, positive and negative reports are coming from the pharmaceutical and agricultural giant, Bayer AG. After the share price reached a 5-year low of EUR 40.36 last week, the first insiders started to buy. Bayer CEO, Werner Baumann, ordered shares worth around EUR 2.45 million. Also, Chief Financial Officer Wolfgang Nickl and Heiko Schipper, responsible for the health products business, increased their portfolio with shares for EUR 154,000 and EUR 309,000 respectively.

Hope for approval

The application for approval of Bayer's renal drug, Finerenon, in the USA and the European Union is also positive. The applications were submitted simultaneously to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Finerenon is considered a new treatment option for slowing the progression of chronic kidney disease. According to industry experts, the drug has a potential of up to EUR 1.5 billion per year.

Sword of Damocles Monsanto

However, the glyphosate controversy continues to dominate all news. The US judge in charge is putting pressure on the Leverkusen-based Company. He wants to resume negotiations in some unresolved cases. Bayer wanted to take the litigation off the table last summer with a large-scale settlement of USD 9.6 billion. However, this settlement was rejected by the court. According to the Bayer leadership, the settlement package increased to around EUR 11.6 billion as of the beginning of November. The uncertainty remains. In the last two weeks, the price of the Bayer stock has recovered by almost 20% and, from a chartist's point of view, is on the verge of the downward trend that began in June and currently stands at just under EUR 49. In the event of a successful breakthrough, the gap to EUR 52.60 should be closed quickly.

NEL ASA keeps hoarding orders

Almost every week the Norwegian hydrogen specialist can shine with new orders. This time the subsidiary, Nel Hydrogen US, received orders for PEM electrolyzer cell stacks worth more than USD 5.4 million from none other than Raytheon Technologies. Nel Hydrogen US is the exclusive supplier of electrolyzer stacks to the United States Navy. The stacks produce vital oxygen for the crews on several classes of nuclear-powered submarines.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

05. March 2021 | 10:35 CET | by Stefan Feulner

Steinhoff, Upco International, ProSiebenSat.1 - Facing a turnaround?

  • Investments

Are the stock indices at the turning point? Although the DAX once again reached new all-time highs this week, there was a lack of momentum to confirm them. A correction is already underway in tech stocks. The market for smartphone payments is also on the move. The Corona pandemic has reinforced the movement away from cash to contactless payment methods. The winners are companies that link multiple business areas.

Read

03. March 2021 | 05:50 CET | by Nico Popp

ProSiebenSat.1 Media, Aspermont, Alibaba: Digital media as a multiplier opportunity

  • Investments

When investors think of the media industry, they often still have stories of declining circulation and dwindling audiences in the back of their minds. But they often forget that media companies have long since made a virtue of necessity and gone digital. It is precisely when traditional media companies' quality meets modern digital groups' possibilities that great opportunities arise for investors. We present three shares.

Read

25. February 2021 | 09:24 CET | by Carsten Mainitz

TAAT, GS Holdings, Aphria - lifestyle and wellness stocks with powerful upside potential

  • Investments

What does lifestyle and wellness encompass for you? Being active? Being pampered? Or a good meal followed by an espresso or a cigarette? The latter has become much less popular with Germans in recent years; the smoking rate has more than halved since 1980. Instead, the trend is toward greater health awareness: light and healthy food, natural supplements and gentle medicine. This trend can be observed worldwide and is continuing successively without any dependence on the economic situation. Because one thing is clear: people are saving money on their health last. Ideal conditions to now look at the securities of the following three companies.

Read